Fawaz O. Alenazy

Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study.

Background Ibrutinib is widely used in B-cell malignancies, yet real-world safety data remain heterogeneous, particularly in underrepresented regional populations. Objective To characterize the adverse-event profile and severity and explore factors associated with Grade 3-5 toxicity and permanent treatment discontinu...